TipRanks
Advertisement
Advertisement
Kyowa Kirin downgraded to Sell from Buy at Citi
PremiumThe FlyKyowa Kirin downgraded to Sell from Buy at Citi
7M ago
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
Premium
The Fly
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
7M ago
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
Premium
The Fly
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
7M ago
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
PremiumThe FlyKyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
10M ago
Kura Oncology receives $30M development milestone payment for ziftomenib
Premium
The Fly
Kura Oncology receives $30M development milestone payment for ziftomenib
12M ago
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
Premium
The Fly
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
1y ago
Kura Oncology price target lowered to $18 from $22 at Scotiabank
PremiumThe FlyKura Oncology price target lowered to $18 from $22 at Scotiabank
2y ago
Kyowa Kirin Advances Share Buyback Program
Premium
Company Announcements
Kyowa Kirin Advances Share Buyback Program
2y ago
Kyowa Kirin Restructures APAC Operations and Licensing
Premium
Company Announcements
Kyowa Kirin Restructures APAC Operations and Licensing
2y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―